MRK Stock Summary and Trading Ideas (Merck Common (New) | NYSE:MRK)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck Common (New) trades on the NYSE stock market under the symbol MRK.

As of February 7, 2025, MRK stock price declined to $87.28 with 14,310,490 million shares trading.

MRK has a market cap of $220.79 billion. This is considered a Mega Cap stock.

Last quarter Merck Common (New) reported $16 billion in Revenue and $1.72 earnings per share. This beat revenue expectation by $114 million and exceeded earnings estimates by $.04.

In the last 3 years, MRK traded as high as $134.63 and as low as $72.88.

The top ETF exchange traded funds that MRK belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.

MRK has underperformed the market in the last year with a price return of -29.1% while the SPY ETF gained +22.0%. MRK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.9% and -8.7%, respectively, while the SPY returned +1.2% and -1.2%, respectively.

MRK support price is $86.72 and resistance is $89.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRK shares will trade within this expected range on the day.